Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)

Table 1 Costs (inflated and discounted) in € by randomization group over a 2-year period

Average cost per patient in € (SD)	First-line coil treatment group	Second-line coil treatment group	P value
0–12 months after randomization	N = 50	N = 50
First coil procedure	14,412 (2358)	NA	NA
Second coil procedure (N = 47)	14,022(2471)	NA	NA
Rehospitalization	1486 (3352)	674 (1983)	0.15
Consultations	984 (1053)	987 (1209)	0.24
Transportation	265 (317)	121 (189)	0.01
Home oxygen	2222 (1925)	2040 (1933)	0.49
Monitoring tests	505 (72)	519 (36)	0.29
Imaging	125 (20)	105 (7)	<.0001
Average total cost during the first year ^a	33,388 (6949)	4446 (2644)	*<.0001*
12–24 months after randomization	N = 46^b	N = 47^b
First coil procedure (N = 40)	NA	14,022 (996)	NA
Second coil procedure (N = 36)	NA	13,465 (501)	NA
Rehospitalization	4912 (19,662)	2897 (4,4862)	0.19
Consultations	460 (630)	647 (1046)	0.005
Transportation	31 (48)	132 (159)	0.002
Home oxygen	2076 (1949)	1790 (1887)	0.51
Monitoring tests	97 (21)	97 (21)	0.44
Imaging	20 (4)	57 (18)	<.0001
Average total cost during the second year for patients alive ^a	7596 (20,035)	27,867 (12,487)	*<.0001*
0–24 months after randomization	N = 50	N = 50
Total cost for 50 patients per group^c	2,018,781	1,536,027	NA
Average total cost per patient	40,376 (21,173)	30,721 (14,364)	*0.07*

^aPatients who did not have the coil treatment have estimated costs of €0
^bPatients alive at 12 months
^cThe ITT population. Patients who died or did not have the coil treatment have estimated costs of €0
The bold datas are number of patients, subtotal and total

ISSN: 1465-993X